Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

26 September 2017 : Clinical Research  

Association of Serum Galectin-3 with the Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Wei Feng1ABCDEF, Xiaojuan Wu1BCD, Shaojun Li1ACDF, Cui Zhai1ABCD, Jian Wang1BCDE, Wenhua Shi1BCDF, Manxiang Li1ACDFG*

DOI: 10.12659/MSM.903472

Med Sci Monit 2017; 23:4612-4618


BACKGROUND: Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) aggravates the overall severity in COPD patients, resulting in severe morbidity and mortality. However, there are no objective biomarkers currently available to predict the development of AECOPD. Several studies have indicated that galectin-3 (Gal-3) is involved in diseases characterized by excessive inflammatory response and fibrosis. The objective of this study was to examine the dynamic changes of Gal-3 in acute exacerbation and convalescence phases of COPD.

MATERIAL AND METHODS: Serum levels of Gal-3, high sensitivity C-reactive protein (hsCRP), and prohormone of brain natriuretic peptide (pro-BNP) were determined using multiplex enzyme-linked immunosorbent assay kits. Serum levels of Gal-3 in 44 patients with COPD were further analyzed and correlated with the parameters of lung function and the biomarkers of systemic inflammation.

RESULTS: The mean level of serum Gal-3 was significantly higher in acute exacerbation of COPD compared with the level in COPD convalescence phase (32.10±9.83 versus 29.02±8.68 ng/mL, p<0.01). Serum levels of Gal-3 positively correlated with hsCRP (r=0.354, p=0.018 for total patients) and pro-BNP (r=0.319, p=0.035 for total patients) in AECOPD. In addition, the level of Gal-3 was the highest in the current smoker group, and the lowest in the never-smoker group in either the acute exacerbation phase (33.91±3.55 versus 29.12±11.73 ng/mL, p=0.036) or the convalescence phase (30.94±3.40 versus 27.76±9.68 ng/mL, p=0.045) of COPD.

CONCLUSIONS: Our results indicated that serum Gal-3 is increased in AECOPD patients, which is also positively associated with systemic inflammation and smoking in patients with COPD, suggesting that Gal-3 might be a valuable biomarker for AECOPD.

Keywords: Biological Markers, Galectin 3, Pulmonary Disease, Chronic Obstructive

Add Comment 0 Comments

879 7


01 September 2023 : Editorial  

Editorial: A Rapid Global Increase in COVID-19 is Due to the Emergence of the EG.5 (Eris) Subvariant of Omicron SARS-CoV-2

Dinah V. Parums
Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA

DOI: 10.12659/MSM.942244

Med Sci Monit 2023; 29:e942244


In Press

21 Sep 2023 : Clinical Research  

The Impact of Implementing the Vortex Approach on Airway Management Performance in Stressed Medical Student...

Med Sci Monit In Press; DOI: 10.12659/MSM.940372  

20 Sep 2023 : Clinical Research  

A Retrospective Study to Compare Pharyngeal Anatomical Changes Measured Before and After Treatment for Malo...

Med Sci Monit In Press; DOI: 10.12659/MSM.941749  

20 Sep 2023 : Database Analysis  

Comparative Finite Element Analysis of Endocrowns and Traditional Restorations for Endodontically Treated M...

Med Sci Monit In Press; DOI: 10.12659/MSM.941314  

19 Sep 2023 : Laboratory Research  

Comparative Evaluation of Dimensional (Vertical/Horizontal) and Occlusal Accuracy of Non-Working Antagonist...

Med Sci Monit In Press; DOI: 10.12659/MSM.941654  

Most Viewed Current Articles

13 Nov 2021 : Clinical Research  

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788


30 Dec 2021 : Clinical Research  

Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...

DOI :10.12659/MSM.935379

Med Sci Monit 2021; 27:e935379

08 Mar 2022 : Review article  

A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...

DOI :10.12659/MSM.936292

Med Sci Monit 2022; 28:e936292

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750